Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1996-10-23
1999-07-27
Saunders, David
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
424 851, 424 852, 424 854, 424 855, 424 857, 435372, 435386, 530351, A61K 3528, A61K 3526, A61K 3819, C12N 508
Patent
active
059286393
ABSTRACT:
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5126132 (1992-06-01), Rosenberg
Slavin, Autologous Stem Cell Transplantation at the National Bone Marrow Transplantation in Jerusalem, A Means for Accomplishing Maximal Tumor Cytroreduction and a Starting Point for Application of Immunotherapy at the Stage of Minimal Residual Disease, Autol. BMT Newsletter, 6:4-6 (1992).
Slavin et al., "Control of Relapse Due to Minimal Residual Disease (MRD) by Cell-Mediated Cytokine-Activated Immunotherapy in Conjunction With Bone Marrow Transplantation", Bailliere's Clin. Haematol., vol. 4, No. 3, pp. 715-725 (Jul. 1991).
Slavin et al., "New Developments in Bone Marrow Transplantation", Current Opinion in Oncology, 3:254-271 (1991).
Slavin, "New Developments in Bone Marrow Transplantation", Pediatric Immunology, vol. 3, pp. 48-65 (1993).
Slavin et al., Cellular-Mediated Immunotherapy of Leukemia in Conjunction with autologous an Allogeneic Bone Marrow Transplantation in Experimental Animals and Man. Blood 72(Suppl. 1): 407a (1988) (abstract).
Slavin et al., Cell-Mediated Cytokine-Activated (CCI) Immunotherapy of Malignant Hematological Disorders for . . . chemotherapy of Bone Marrow Transplantation. Blood 76(Suppl.):2254a (1990) (abstract).
Slavin et al., Eradication of Minimal Residual Disease (MDR) Following Autologous (ABMT) and Allogeneic Bone Marrow Transplantation (BMT) by . . . in Experimental Animals and Man. Blood 80:535a (1992) (abstract).
Nagler et al., Adoptive Immunotherapy with Mismatched Allogenic Peripheral Blood Lymphocytes (PBL) Following Autologous Bone Marrow Transplantation (ABMT). Exp. Hematol. 20: 705 (1992) (Abstract).
Slavin et al., Immunotherapy of Minimal Residual Disease in Conjunction With Autologous and Allogeneic Bone Marrow Transplantation (BMT). Leukemia (England) 6 (Suppl. 4):164-66 (1992).
Slavin et al., Immunotherapy of Minimal Residual Disease by Immunocompetent Lymphocytes and their activation by Cytokines. Cancer Invest. 10: 221-227 (1992).
Slavin et al., Induction of Cell-Mediated Il-2-Activated Antitumor Responses in Conjunction with Autologous and Allogeneic Bone Marrow Transplantation. Transplant. Proc. 23: 802-03 (1991).
Johnson et al., Delayed Infusion of Normal Donor Cells After MHC-Matched Bone Marrow Transplantation Provides an Antileukemia Reaction Without Graft-Versus-Host Disease. Bone Marrow Transplant. 11: 329-336 (1993).
Sykes et al., Achieving Alloengraftment Without Graft-Versus-Host Disease: Approaches Using Mixed Allogeneic Bone Marrow Transplantation. Bone Marrow Transplant. 3: 379-86 (1988).
Sykes et al., Interleukin 2 Prevents Graft-Versus-Host Disease While Preserving the Graft-Versus-Leukemia Effect of Allogeneic T Cells. Proc. Natl. Acad. Sci. USA 87: 5633-37 (1990).
Samuel et al., Effects of Interleukin 2 on Engraftment Following Autologous Bone Marrow Transplantation (ABMT) in Dogs. Leukemia Res. 16: 967-72 (1992).
Ackerstein et al., Use of Recombinant Human Interleukin-2 in Conjunction with Syngeneic Bone Marrow Transplantation in Mice as a Model for Control of Minimal Residual Disease . . . Blood 78: 1212-15 (1991).
Slavin et al., Induction of Cell-Mediated IL-2 Activated Antitumor Responses in Conjunction with Autologous and Allogeneic Bone Marrow Transplantation. Transplant. Proc. 23: 802-03 (1991).
Slavin et al., The Graft-Versus-Leukemia (GVL) Phenomenon: Is GVL Separable from GVHD? Bone Marrow Transplant. 6: 155-61 (1990).
Slavin et al., I1-2 Activated Cell-Mediated Immunotherapy: Control of Minimal Residual Disease in Malignant Disorders by Allogeneic Lymphocytes and I1-2. Bone Marrow Transplant. 6 (Suppl. 1): 86-90 (1990).
Eckerstein et al., Immunotherapy in Conjunction with Autologous Bone Marrow Transplantation. Bone Marrow Transplant. 5 (Suppl. 1): 38 (1990).
Slavin et al., Toward Improvement of Therapeutic Strategies in Leukemia by Amplification of the Immune Response Against Leukemia. Haematol. and Blood Transfusion 13: 36-40 (1990).
Mule et al., The Anti-Tumor Efficacy of Lymphokine-Activated Killer Cells and Recombinant Interleukin 2 In Vivo. J. Immunol. 135: 1-7 (1985).
Weiss et al., Use of Recombinant Human Interleukin-2 in Conjunction with Bone Marrow Transplantation as a Model for Control of Minimal . . . I. Treatment of Murine Leukemia Cancer Invest. 10: 19-26 (1992).
Rosenberg, S.A., Adoptive Immunotherapy of Cancer: Accomplishments and Prospects. Cancer Treatment reports 68: 233-55 (1984).
Mule et al., Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2. Science 255: 1487-89 (1984).
Slavin et al., New Therapeutic Strategies for Autologous and Allogeneic Bone Marrow Transplantation. Exp. Hematol. 15: 595 (1987).
Truitt and Atasoylu, Impact of Pretransplant Conditioning and Donor T Cells on Chimerism, Graft-Versus-Host Disease, Graft-Versus-Leukemia Reactivity, and Tolerance After Bone . . . Blood 77:2515-23 (1991).
Cheever et al., Augmentation of the Anti-Tumor Therapeutic Efficacy of Long-Term Cultured T Lymphocytes by In Vivo Administration of Purified Interleukin 2. J. Exp. Med. 155: 968-80 (1982).
Napler et al p. 705, Abstr. #2 in Experimental Hematology, 20(6), 1997.
Slavin et al Abstract #2254, p. 566a in Bone Marrow Transplantation, 1990.
Slavin et al Leukemia 6: 164, 1992.
Hadasit Medical Research Services and Development Ltd.
Saunders David
VanderVegt F. Pierre
LandOfFree
Immunotherapy of cancer with allogeneic lymphocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of cancer with allogeneic lymphocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of cancer with allogeneic lymphocytes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-875929